Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,561 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery of S-444823, a potent CB1/CB2 dual agonist as an antipruritic agent.
Odan M, Ishizuka N, Hiramatsu Y, Inagaki M, Hashizume H, Fujii Y, Mitsumori S, Morioka Y, Soga M, Deguchi M, Yasui K, Arimura A. Odan M, et al. Among authors: fujii y. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2898-901. doi: 10.1016/j.bmcl.2012.02.050. Epub 2012 Feb 23. Bioorg Med Chem Lett. 2012. PMID: 22421019
CB 1/2 dual agonists with 3-carbamoyl 2-pyridone derivatives as antipruritics: reduction of CNS side effects by introducing polar functional groups.
Odan M, Ishizuka N, Hiramatsu Y, Inagaki M, Hashizume H, Fujii Y, Mitsumori S, Morioka Y, Soga M, Deguchi M, Yasui K, Arimura A. Odan M, et al. Among authors: fujii y. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2894-7. doi: 10.1016/j.bmcl.2012.02.054. Epub 2012 Mar 3. Bioorg Med Chem Lett. 2012. PMID: 22437111
Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent.
Odan M, Ishizuka N, Hiramatsu Y, Inagaki M, Hashizume H, Fujii Y, Mitsumori S, Morioka Y, Soga M, Deguchi M, Yasui K, Arimura A. Odan M, et al. Among authors: fujii y. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2803-6. doi: 10.1016/j.bmcl.2012.02.072. Epub 2012 Mar 3. Bioorg Med Chem Lett. 2012. PMID: 22444677
Pyrrolidine inhibitors of human cytosolic phospholipase A(2).
Seno K, Okuno T, Nishi K, Murakami Y, Watanabe F, Matsuura T, Wada M, Fujii Y, Yamada M, Ogawa T, Okada T, Hashizume H, Kii M, Hara S, Hagishita S, Nakamoto S, Yamada K, Chikazawa Y, Ueno M, Teshirogi I, Ono T, Ohtani M. Seno K, et al. Among authors: fujii y. J Med Chem. 2000 Mar 23;43(6):1041-4. doi: 10.1021/jm9905155. J Med Chem. 2000. PMID: 10737736 No abstract available.
Discovery of clinical candidate Sivopixant (S-600918): Lead optimization of dioxotriazine derivatives as selective P2X3 receptor antagonists.
Kai H, Horiguchi T, Kameyma T, Onodera N, Itoh N, Fujii Y, Ichihashi Y, Hirai K, Shintani T, Nakamura K, Minami K, Kasai E, Yoneda S, Murakami Y, Ogawa H, Sekimoto R, Shinohara S, Yoshida O, Kurose N. Kai H, et al. Among authors: fujii y. Bioorg Med Chem Lett. 2021 Nov 15;52:128384. doi: 10.1016/j.bmcl.2021.128384. Epub 2021 Sep 26. Bioorg Med Chem Lett. 2021. PMID: 34587541 Free article.
Development and validation of nomograms and integrated software incorporating preoperative C-reactive protein level for prognostic prediction of nonmetastatic clear cell renal cell carcinoma: Results from the International Marker Consortium for Renal Cancer (INMARC) Registry.
Chen W, Tanaka H, Kobayashi M, Fukuda S, Nakayama A, Meagher MF, Greenwald R, Schmeusser B, Nicase E, Waseda Y, Yoshida S, Derweesh IH, Master VA, Fujii Y, Saito K. Chen W, et al. Among authors: fujii y. World J Urol. 2025 Jan 9;43(1):63. doi: 10.1007/s00345-024-05421-3. World J Urol. 2025. PMID: 39786437
4,561 results